Induced pluripotent stem cells (iPSCs) could be generated by a single gene Oct4 and chemical compounds, in which exogenous expression of Oct4 was indispensable for reprogramming. Recent advances in chemical-mediated cellular reprogramming suggest that small molecules alone (i.e. without Yamanaka factors) can successfully establish iPSCs from mouse somatic cells.
Induced pluripotent stem cells (iPSCs) were first established with the introduction of four transcription factors by viral transduction. Ever since this epoch-making discovery, several advances that generate iPSCs with fewer exogenous genetic manipulations are taking place at an astonishing pace, among which the most promising way to generate clinical grade iPSCs is employing chemical compounds that can replace exogenous reprogramming factors (Ma et al., 2013) ; ultimately, with zero genes and only chemical compounds. Chemical compounds are advantageous in that they are readily accessible to the cells, cost-effective and can be easily manipulated. Recent studies have shown that mouse or human somatic cells can be reprogrammed by Oct4 and chemical compounds (Zhu et al., 2010; Li et al., 2011; Yuan et al., 2011) . Deng and colleagues have identified a small-molecule combination, called 'VC6T' [valproic acid (a HDAC inhibitor), CHIR99021 (a GSK3 inhibitor), 616 452 (a TGF-b inhibitor), tranylcypromine (Parnate; a LSD1 inhibitor)], which enables reprogramming in mouse cells with a single gene Oct4 (Li et al., 2011) . Further improvement with the goal of finding a potent 'Oct4 replacer' is expected to bring the chemical-only reprogramming strategy into reality.
Recently, the same group (Deng and colleagues) found forskolin (FSK), a cAMP agonist, as a chemical substitute for Oct4, after screening 10000 small-molecules using Oct4 promoter-driven GFP-expressing MEFs (Hou et al., 2013) . Combined with their previous study (Li et al., 2011) , they showed that VC6T plus FSK (VC6TF) induced GFP-positive clusters; however, Oct4 expression was not detectable and its promoter remained hypermethylated, suggesting a repressed epigenetic state. While screening for small-molecule boosters during late stages of the reprogramming process, they found that GFP-positive cells were obtained more frequently with the addition of DZNep (an epigenetic modulator) after 16 days of VC6TF treatment (VC6TFZ). However, in the resultant GFP-positive cells, the expression of pluripotency genes was still lower than that in embryonic stem cells (ESCs), suggesting an incomplete reprogramming state. After 28 days posttreatment, they switched to 2i-medium (dual inhibition of GSK3 and MEK), and then GFP-positive colonies developed an ESC-like morphology, which were further validated as chemically induced pluripotent stem cells (CiPSCs) (Figure 1) (Hou et al., 2013) . Additional optimization studies subsequently identified TTNPB (a synthetic retinoic acid receptor ligand) as a small-molecule booster for chemical reprogramming. On the other hand, they also determined four compounds in the cocktail 'C6FZ' as minimal essential small-molecules for CiPSC generation (Figure 1) . Collectively, they demonstrate that, using seven small-molecule compounds, CiPSCs can be generated from mouse somatic cells with a frequency up to 0.2% (a frequency comparable with transcription factorinduced reprogramming). Interestingly, the chimeric mice generated from CiPSCs were 100% viable and healthy. Regarding the mechanism during chemical reprogramming, they found that 'C6F' induced Sall4 and Sox2 expression in the early phase, whereas DZNep enhanced Oct4 expression in the late phase. At 2i stage, Oct4 and Sox2 may activate pluripotency-related genes, along with the activation of Nanog (Hou et al., 2013) .
In this study, safety issue still needs to be addressed for chemical-based reprogramming. Although there is no risk of insertional mutagenesis, it is important to know whether chemical cocktails induce genetic instability during reprogramming process that compromise genetic integrity of resultant CiPSCs. Furthermore, although in vivo differentiation capacity of CiPSCs was extensively examined (Hou et al., 2013) , in vitro differentiation capacity also needs to be evaluated. It would be interesting to further examine whether different CiPSC lines are biased toward particular lineages after differentiation and whether epigenetic memories are still retained after reprogramming. Regarding cell type of origin, CiPSCs were obtained not only from MEFs, but also from mouse neonatal fibroblast, mouse adult fibroblasts, and adipose-derived stem cells (Hou et al., 2013) . Considering the accessibility of cells in humans, other cell types, such as blood cells, should be further investigated. The major disadvantage in CiPSCs is the time-consuming process of reprogramming. Given that it takes about 40 days to induce CiPSCs even in mouse cells (Hou et al., 2013) , it may require a longer period ( 60 days) to obtain human CiPSCs. To achieve a shorter reprogramming process, strategy for rapidly inducing CiPSCs should be developed.
The method by Hou et al. (2013) might have synergistic or additive effects on reprogramming with other emerging strategies, including Oct4 activator (Li et al., 2012) , compound d , toll-like receptor 3 (TLR3) agonist (Lee et al., 2012) , and hypoxia. In particular, compound d is a novel synthetic small-molecule that could rapidly induce multiple pluripotency genes in MEFs . Compound d is a kind of dual functional compounds, called SAHA-PIPs. Unlike other smallmolecules currently employed to enhance cellular reprogramming efficacy, the PIPs (Pyrrole-Imidazole polyamides) in SAHA could be pre-programmed to bind specific DNA sequences (Pandian and Sugiyama, 2012) . In this way, the chromatin modifying HDAC inhibitor, SAHA, could be directed to desired gene(s) of interest with programmable, tailor-made SAHA-PIPs.
In the near future, human CiPSCs would be established, with some modifications on current protocol. For example, 2i culture condition enables mouse ESCs to be maintained in the ground state (i.e. a naïve state). Since human ESCs are considered more similar to mouse EpiSCs (i.e. a primed state), various strategies have been developed to derive 'naïve' human ESCs/iPSCs. Among these efforts, Hanna et al. (2010) rewired 'primed' human ESCs into a more primitive state like mouse ESCs. Converted 'naïve' human ESCs could be maintained using 2i/ LIF/FSK and were independent of ectopic transgene expression; however, they could not be maintained long-term in culture and thus this warrants further improvement.
Taken together, this is the first report (Hou et al., 2013) Figure 1 Schematic representation of the process during mouse CiPSC generation. 'VC6T' cocktail has been known as 'Sox2-Klf4 -c-Myc replacer' (Li et al., 2011) . Although Forskolin has been identified as 'Oct4 replacer', resultant cocktail 'VC6TF' is not sufficient for reprogramming. Repressed expression of Oct4 is recovered by adding DZNep, an epigenetic modulator, at later stage. However, 'VC6TFZ' still leads to incomplete reprogramming, which is resolved by 2i treatment. In this chemical process, step-wise establishment of pluripotency circuitry is required for CiPSC generation (Hou et al., 2013) . Standard cocktail is 'VC6TFZ' plus 2i, whereas minimal essential cocktail is 'C6FZ' plus 2i. Optional compound is TTNPB. CiPSC, chemically induced pluripotent stem cell; V, valproic acid (a HDAC inhibitor); C, CHIR99021 (a GSK3 inhibitor); 6, 616452 (a TGF-b inhibitor); T, tranylcypromine (Parnate, a LSD1 inhibitor); F, forskolin (a cAMP agonist); Z, DZNep (an SAH hydrolase inhibitor); P, PD0325901 (a MEK inhibitor); T, TTNPB (a synthetic retinoic acid receptor ligand); 2i, dual inhibition (CHIR99021 plus PD0325901).
